Registry for genomic medicine in lung cancer in Germany
Registry of the National Network Genomic Medicine Lung Cancer (nNGM), Linking Data on Molecular Diagnostics, Clinical Characteristics, Treatment Patterns and Outcomes of Subjects With Non-Small Cell Lung Cancer in Germany
This study is collecting information from lung cancer patients in Germany to see how their treatment and outcomes can be improved.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Cologne Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Cologne) |
| Trial ID | NCT05934032 on ClinicalTrials.gov |
What this trial studies
This registry collects and analyzes data on molecular diagnostics, clinical characteristics, treatment patterns, and outcomes for patients with non-small cell lung cancer (NSCLC) across Germany. It involves 23 specialized cancer centers and over 400 hospitals and oncological practices, providing a comprehensive overview of patient journeys from diagnosis to treatment outcomes. The registry aims to improve understanding of NSCLC through standardized procedures and continuous evaluation of clinical outcomes based on collected data.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with histologically confirmed locally advanced or metastatic non-small cell lung cancer.
Not a fit: Patients with resectable NSCLC or those who cannot provide written informed consent may not benefit from this registry.
Why it matters
Potential benefit: If successful, this registry could enhance personalized treatment approaches and improve outcomes for patients with non-small cell lung cancer.
How similar studies have performed: Other similar registries have shown success in improving treatment outcomes and understanding of cancer, indicating that this approach is promising.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Histologically confirmed, locally advanced or metastatic NSCLC (Union for International Cancer Control \[UICC\] stage IIIb/IV; non-resectable NSCLC) * From 07/2023: histologically confirmed NSCLC stage Ib, II, III (UICC) Exclusion Criteria: * Missing written informed consent
Where this trial is running
Cologne
- University Hospital Cologne — Cologne, Germany (Recruiting)
Study contacts
- Study coordinator: Anna Rasokat
- Email: anna.rasokat@uk-koeln.de
- Phone: 004922147896992
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.